Fully Natural Lecithin Encapsulated Nano-Resveratrol for Anti-Cancer Therapy

 You can check out why your doctor should be prescribing resveratrol in these.

• resveratrol (60 posts to January 2012)

• resveratrol analogues (1 post to November 2017)

• resveratrol preconditioning (2 posts to July 2015)

Your stroke researcher should immediately be figuring out how this can be applied to stroke rehab.

Fully Natural Lecithin Encapsulated Nano-Resveratrol for Anti-Cancer Therapy

     

Authors Liang M, Guo M, Saw PE , Yao Y 

Received 22 February 2022

Accepted for publication 22 April 2022

Published 6 May 2022 Volume 2022:17 Pages 2069—2078

DOI https://doi.org/10.2147/IJN.S362418

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Yan Shen

Download Article [PDF] 

Meiyi Liang,^1,2,* Mingyan Guo,^1,3,* Phei Er Saw,^1,4 Yandan Yao<sup>1,2,5

1</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, People’s Republic of China; ²Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, People’s Republic of China; ³Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, People’s Republic of China; ⁴Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, People’s Republic of China; ⁵Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei, 516621, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yandan Yao; Phei Er Saw, Email yaoyand@mail.sysu.edu.cn; caipeie@mail.sysu.edu.cn

Introduction: Chemotherapeutics are known to have undesirable side effects (i.e. nausea, weight loss, hair loss, weakened immune system, etc.) due to the non-specificity of the drugs. Encapsulation of these chemotherapeutics inside nanoparticles significantly improves the bioavailability and half-life of drugs, while increasing their tumor penetration and localization. However, most, if not all, nanoparticles in clinics or research are synthetic, with no long-term studies on the effect of these nanoparticles in vivo. Herein, we developed a synergistic resveratrol nanoparticle system by using lecithin encapsulation. Lecithin, being a fully natural phospholipid derived from soybean, possesses inherent anti-tumor activity.
Methods: Lec(RSV) was successfully prepared using the nanoprecipitation method, and characterized by particle size and zeta potential analysis, and transmission electron microscopy (TEM). The in vitro cellular uptake and cytotoxic effects of Lec(RSV) were investigated in human breast cancer cell line BT474. Finally, the in vivo tumoral uptake of Lec(RSV) was carried out in the BT474 orthotopic model.
Results: Lec(RSV) showed a uniform distribution of ∼ 120 nm, with prolonged stability. Lec(RSV) showed high cellular uptake and anti-cancer properties in vitro. Time-dependent uptake in the BT474 xenograft model indicated an increased tumoral uptake and apoptosis rate at 4 hours after tail vein injection of Lec(RSV).
Conclusion: Taken together, we successfully developed a fully natural Lec(RSV) that possesses potent anti-cancer activity in vitro, with good tumoral uptake in vivo. We hypothesize that Lec(RSV) could be a safe anti-cancer therapeutic that could be easily translated into clinical application.

 

Statistical Considerations for Drawing Conclusions About Recovery

 So our researchers know nothing about what their research says.

Statistical Considerations for Drawing Conclusions About Recovery

 

Show all authors

Keith R. Lohse, PhD, Rachel L. Hawe, DPT, PhD, Sean P. Dukelow, MD, PhD, ...

First Published December 14, 2020 Research Article 

https://doi.org/10.1177/1545968320975437

Article information

 

Abstract

Background

Numerous studies have found associations when change scores are regressed onto initial impairments in people with stroke (slopes ≈ 0.7). However, there are important statistical considerations that limit the conclusions we can draw about recovery from these studies.

Objective

To provide an accessible checklist of conceptual and analytical issues on longitudinal measures of stroke recovery. Proportional recovery is an illustrative example, but these considerations apply broadly to studies of change over time.

Methods

Using a pooled data set of n = 373 Fugl-Meyer Assessment upper extremity scores, we ran simulations to illustrate 3 considerations: (1) how change scores can be problematic in this context; (2) how “nil” and nonzero null-hypothesis significance tests can be used; and (3) how scale boundaries can create the illusion of proportionality, whereas other analytical procedures (eg, post hoc classifications) can augment this problem.

Results

Our simulations highlight several limitations of common methods for analyzing recovery. We find that uniform recovery leads to similar group-level statistics (regression slopes) and individual-level classifications (into fitters and nonfitters) that have been claimed as evidence for the proportional recovery rule. New analyses, however, also speak to the complexities in variance about the regression slope.

Conclusions

Our results highlight that one cannot identify whether proportional recovery is true or not based on commonly used methods. We illustrate how these techniques, measurement tools, and post hoc classifications (eg, nonfitters) can create spurious results. Going forward, the field needs to carefully consider the influence of these factors on how we measure, analyze, and conceptualize recovery.

Keywords stroke, rehabilitation, methods, data analysis

Access Options